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BACKGROUND: Acute variceal haemorrhage is a complication of cirrhosis that can be life threatening. It is a pharmacist’s duty to ensure 
therapeutic and pharmaceutical care which is not only 
safe and effective for the patient but also is cost-effective 
in order to attain improvement of the patient’s quality of 
life. Therefore, pharmacoeconomic evaluation especially 
cost-effectiveness analysis (CEA), which compares costs 
and consequences of drug therapy, is needed. This study 
was aimed to evaluate the therapeutic cost-effectiveness of 
hematemesis-melena treatment in hepatic cirrhotic patients.
METHODS: A total of 42 patients receiving vitamin K 
and vitamin K-transamin were studied retrospectively from 
patients’ medical records in 2 years and analyzed with 
cost-effectiveness grid and average cost-effectiveness ratio 
(ACER) based on Child-Turcotte-Pugh (CTP) Score.
RESULTS: Cost-effectiveness grid was dominant for 
vitamin K in patients with CTP Score A. ACER analysis 
showed a lower score for vitamin K in all patients included 
CTP Score classification. There was no significant difference 
in duration of cessation of bleeding treatment in patients with 
vitamin K compared with vitamin K-transamin in patients 
with CTP Score A and B, while significant difference was 
found in patients with CTP Score C.
CONCLUSION: Vitamin K appeared to be more cost-
effective as compared with vitamin K-transamin in all 
patients. The use of vitamin K had greater benefit than the 
combination with transamin in all patients and CTP Score 
classification, and thus should be considered as a primary 
therapy. Therefore, transamin addition as an alternative 
therapy for hepatic cirrhosis patients with hematemesis-
LATAR BELAKANG: Pendarahan varises akut merupakan komplikasi sirosis yang dapat mengacam jiwa. Hal ini merupakan tugas farmasis 
untuk memastikan terapi dan pelayanan kefarmasian yang 
tidak hanya aman bagi pasien tetapi juga mempunyai 
biaya yang efektif yang bertujuan untuk memperbaiki 
kualitas hidup pasien. Oleh karena itu, diperlukan evaluasi 
farmakoekonomi terutama cost-effectiveness analysis 
(CEA) yang membandingkan biaya dan konsekuensi dari 
terapi hematemesis-melena pada pasien sirosis hepatik.
METODE: Total dari 42 pasien yang menerima vitamin 
K dan vitamin K-transamin diteliti secara retrospektif dari 
rekam medik selama 2 tahun, dan dianalisis dengan cost-
effectiveness grid dan average cost-effectiveness ratio 
(ACER) berdasarkan Child-Turcotte-Pugh (CTP) Score.
HASIL: Cost-effectiveness grid menunjukkan bahwa 
dominant untuk vitamin K pada pasien dengan CTP Score 
A. Analisis ACER menunjukkan nilai yang lebih rendah 
pada vitamin K pada semua pasien meliputi klasifikasi CTP 
Score. Tidak ada perbedaan bermakna untuk durasi dari 
penghentian terapi pendarahan pada pasien dengan vitamin 
K dibandingkan dengan vitamin K-transamin pada pasien 
dengan CTP Score A dan B, sedangkan perbedaan signifikan 
ditemukan pada pasien dengan CTP Score C.
KESIMPULAN: Vitamin K terbukti lebih efektif biaya 
dibandingkan dengan vitamin K-transamin pada semua 
pasien. Penggunaan vitamin K memiliki keuntungan yang 
lebih besar dibandingkan dengan kombinasi dari transamin 
pada semua pasien dan klasifikasi CTP Score, sehingga 
seharusnya dipertimbangkan sebagai terapi primer. Oleh 
karena itu penambahan transamin sebagai terapi alternatif 
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The liver is a major site of metabolism of various drugs. In 
patients with liver disease the liver capacity for metabolism/ 
elimination of drugs may be disturbed.(1) Cirrhosis of the 
liver (hepatic cirrhosis) is one of the severe liver diseases 
that is chronic, irreversible, and causes high mortality(2), 
and this occupies the twelfth leading cause of death in the 
United States(3).
 Hepatic cirrhosis is a diffuse process characterized by 
fibrosis and changes of the normal liver structure to abnormal 
nodule structure.(4) As a result, scar tissue is formed due to 
injury or long-term liver disease, and it causes the liver to 
fail its normal functions such as protein synthesis, cleaning 
process of the blood, resistance to infection, digesting 
foods, and energy storage.(5) The degree of severity of the 
liver disease can be divided into three categories with Child-
Turcotte-Pugh (CTP) Score. CTP Classification is a system 
used to classify the degree of liver damage or development 
of liver disease in hepatic cirrhosis patients.(6,7)
 There are some complications of cirrhosis such 
as ascites, hepatic encephalopathy (HE), hepatorenal 
syndrome, SBP (spontaneous bacterial peritonitis), and 
esophageal varices.(3) Fifty percent of patients with 
melena should be considered.
KEYWORDS: CEA, cost-effectiveness analysis, Child-
Turcotte-Pugh Score, hepatic cirrhosis, hematemesis-
melena, vitamin K, transamin
Indones Biomed J. 2013; 5(1): 43-50
pada pasien sirosis hepatik harus dipertimbangkan.
KATA KUNCI: CEA, cost-effectiveness analysis, Child-
Turcotte-Pugh Score, sirosis hepatik, hematemesis-melena, 
vitamin K, transamin
alcoholic cirrhosis will develop esophageal varices after 
2 years after being diagnosed, and 70-80% patients in 
10 years. About 25-35% patients with cirrhosis and large 
esophageal varices will experience variceal haemorrhage. 
Acute variceal haemorrhage is a complication of cirrhosis 
which has life threatening impact(2), and acts as a major 
cause of death in cirrhosis patients(8). The increase in portal 
pressure due to increased resistance to blood flow to the 
liver is largely due to the distortion of the liver structure 
to fibrous tissue and regenerative nodules and intra hepatic 
active vasoconstriction by 20% -30% of the increased intra 
hepatic resistance, and a decrease in endogenous production 
of nitric oxide.(9)
 One of the functions of the liver is to produce several 
clotting factors (including prothrombin and fibrinogen) 
as well as to produce bile salts that are necessary for 
gastrointestinal absorption of vitamin K, which is needed to 
produce coagulation factor.(10) Deficiency in vitamin K can 
cause blood clotting disorders, to cause the patients to be 
prone to bleeding. On the other hand, transamin (tranexamic 
acid (TXA)), which is an antifibrinolytic agent, has 
proven useful for controlling bleeding in some conditions, 
especially is more favorable in small superficial lesions 
such as gastric erosion and in esophageal varices(11), and 
proven to provide  cost-effectiveness  in cirrhosis(12).
 Neff et al. had examined the economic impact of 
Introduction
1 2 3
Ascites None Slight Moderate / Severe
Encephalopathy None Slight / Moderate Moderate / Severe
Bilirubin (mg/dL) < 2.0 2-3 > 3.0
Albumin (mg/L) > 3.5 2.8-3.5 < 2.8
Prothrombin time (seconds, increased) 1-3 4-6 > 6.0
Parameter
Numerical Score
Table 1. CTP Score.(6)
Total Numerical Score CTP Class
5-6 A
7-9 B
10-15 C
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Methods
various regimens used for prophylaxis and treatment of 
cirrhosis-related complications, and found it necessary to 
evaluate the costs and complications of cirrhosis-related 
complications.(13)
 Cost-effectiveness analysis (CEA)  used in accordance 
to the study objectives in assessing relationship between 
cost and outcome, which in this case is clinical outcome, 
and CEA is an important instrument in setting priorities for 
strategic planning of therapy. By measuring and comparing 
cost and consequences of an intervention, efficient 
relationship could be assessed and the resources needed in 
the future could be estimated.(14)
This study was a non-experimental research and used the 
retrospective approach. Data were obtained from adult 
patients’ medical records which had major diagnosed 
hepatic cirrhosis cases.
 In this study, the method used was CEA. Therapeutic 
cost and consequences of therapy were measured and 
compared.
Research variables
Dependent variables in this study were cost (cost of vitamin 
K and combination of vitamin K-transamin) and clinical 
outcome (duration of cessation of bleeding). Independent 
variables in this study were type of treatment and CTP score.
Population and sample
Population in this study was all the hospitalized hepatic 
cirrhosis patients with hematemesis-melena at Adi Husada 
Undaan Wetan Hospital, from January 2010 to December 
2011. Patients were grouped based on their degree of liver 
disease with CTP score.
 The number of samples was calculated based on 
formula(15):
 N = p.q. (Z
1/2a/b)
2
N  = minimum sample number
p  = percentage proportion in first population group
q  = percentage proportion in second population  
     group = 1-p
Z
1/2α
  = degree of confidence coefficient in certain level  
     of confidence (example 95 or 99%)
b  = estimate percentage error possibility on number   
     of sample determination (about 0.1 or 0.5)
Calculation of sample’s number in this study:
N = p.q. (Z
1/2a/b)
2 = 0.5 x 0.5 x (1.96/0.2)2 = 24 patients
Thus, the number of samples needed in each intervention 
group was 6 patients.
Inclusion and Exclusion Criteria
Inclusion criteria in this study were hepatic cirrhosis patients 
with hematemesis-melena, adult age ≥ 16 years (16), and 
patients treated with vitamin K or combination of vitamin 
K-transamin.  Exclusion criteria were patients who went 
home before the bleeding stopped, had not improved their 
clinical outcome, or died; patients who had not recovered 
from bleeding; patients with another kind of disease like 
hepatoma, or used another medication (for example oral 
vitamin K or oral transamin), which could interfere the 
treatment studied and outcome relationship; incomplete 
patient’s medical record including diagnoses or clinical 
outcomes.
Data Analysis Techniques
Data obtained were analyzed with statistical method. 
First the normality of data was examined, then parametric 
(Anova one way, independent t-Test, and pooled t-Test) or 
non-parametric tests (Kruskal Wallis and Mann Whitney 
U test) were used to know the difference in duration of 
treatment until the bleeding stopped and the costs. Degree 
of significance used for the tests was 0.05 and the statistical 
program used was SPSS 17.0. Besides, conclusions were 
also made using cost-effectiveness grid and average cost-
effectiveness ratio (ACER) calculation.
Calculation of ACER
ACER was calculated based on the following formula(5) : 
ACER  = cost / effectiveness.Results
Effectiveness was calculated based on the percentage of 
cumulative duration of treatment until improvement was 
less than or equal to 1 day in all patients and in patients with 
CTP Score A and B, as well as the duration of treatment to 
improve less than or equal to 3 days in patients with CTP 
Score C. CTP Based on the effectiveness of therapy, in 
patients with CTP Score A found that vitamin K was more 
effective than vitamin K-effectiveness transamin although 
the difference was rather slight, in all patients and patients 
with CTP Score B and C, the effectiveness of vitamin 
K-transamin was greater than vitamin K. While the cost of 
treatment was only calculated based on the average cost of 
the therapeutic use of vitamin K and vitamin K-transamin 
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based on the length of treatment to get better. The higher 
the severity of liver cirrhosis, the longer the treatment will 
take and therefore contributes to the increasing number of 
drugs used to stop bleeding and will ultimately affect the 
cost of the used drugs. Based on calculation with ACER, it 
showed that vitamin K was more cost-effective than vitamin 
K-transamin in all patients as well as patients with CTP 
Score A, B, and C.
 At the test time difference of improving the treatment 
of the samples using parametric and nonparametric methods 
Table 3. Patients Cahracteristics
Data presented as mean + standard deviation. Significant difference if p ≤ 0.05.
Lower Equal Higher
Higher + (dominant) + +/- (trade off)
Equal + Arbitrary -
Lower +/- (trade-off) -  - (dominated)
Cost of Alternative A Relative to Alternative B
Effectiveness of Alternative A 
Relative to Alternative B
Table 1. Cost-Effectiveness Grid for CEA.
Whole Group (n=42) CTP Score A (n=13) p value
Gender, male 29 (69.05%) 7 (53.85%) 14 (93.33%) 8 (57.14%) 0.227
Gender, female 13 (30.95%) 6 (46.15%) 1 (6.67%) 6 (42.86%) 0.146
Age, years 59.12 ± 13.41 59.08 ± 9.40 54.80 ± 15.46 63.79 ± 13.53 0.057
Arterial systolic pressure, mmHg 121.62 (101.67-162.67) 111.63 (101.67-162.67) 122 (102.50-135.80) 122.96 (102.56-157) 0.612
Arterial diastolic pressure, mmHg 67.67 (54-89) 69.60 (58.67-89) 69.67 (60.43-77.33) 63.40 (54-84.80) 0.541
Therapy
     Vitamin K 18 (42.86%) 7 (53.85%) 5 (33.33%) 6 (42.86%) 0.846
     Vitamin K-Transamin 24 (57.14%) 6 (46.15%) 10 (66.67%) 8 (57.14%) 0.607
Cost
     Vitamin K (IDR) 12,641 (8,471) 5,550 (0) 11,100 (3,924) 22,200 (7,020) 0.000
5,550 (0) 11,100 (3,924) 22,200 (7,020) 0.054
5,550 (0) 11,100 (3,924) 22,200 (7,020) 0.000
0.001
     Vitamin K-Transamin (IDR) 62,643 (31,773) 44,975 (15,737) 53,970 (26,954) 86,737 (34,170) 0.033
44,975 (15,737) 53,970 (26,954) 86,737 (34,170) 0.519
44,975 (15,737) 53,970 (26,954) 86,737 (34,170) 0.025
0.042
Hospitalization duration 6 (3-14) 6 (3-14) 5 (3-14) 8.5 (3-14) 0.000
6 (3-14) 5 (3-14) 8.5 (3-14) 0.230
6 (3-14) 5 (3-14) 8.5 (3-14) 0.000
0.000
Duration of treatment to bleed stopped 1.5 (1-6) 1 (1-5) 1 (1-6) 2.5 (1-5) 0.000
1 (1-5) 1 (1-6) 2.5 (1-5) 0.023
1 (1-5) 1 (1-6) 2.5 (1-5) 0.000
0.003
Duration of treatment 4 (1-14) 3 (1-7) 3 (2-9) 7 (2-14) 0.002
3 (1-7) 3 (2-9) 7 (2-14) 0.673
3 (1-7) 3 (2-9) 7 (2-14) 0.001
0.005
CTP Score B (n=15) CTP Score C (n=14)
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Vitamin K (n=7) Vitamin K-Transamin (n=6) p value
Gender, male 3 (42.86%) 4 (66.67%) 0,705
Gender, female 4 (57.14%) 2 (3.33%) 0,414
Age, years 64 ± 10.50 53.33 ± 2.50 0,034
Arterial systolic pressure, mmHg 130.33 (101.67-140.56) 114.9 (101.86-162.67) 0.860
Arterial diastolic pressure, mmHg 62.67 (58.67-75.22) 74.17 (61.71-91.12) 0,027
Hospitalized duration 4 (3-9) 4 (3-8) 1.000
Duration of treatment to bleed stopped 1 (1-1) 1 (1-2) 0.280
Duration of treatment 3 (1-7) 3.5 (2-6) 0,941
Cost 5,550 (0) 44,975 (15,737) 0,001
Vitamin K (n=5) Vitamin K-Transamin (n=10) p value
Gender, male 4 (80%) 10 (100%) 0,109
Gender, female 1 (20%) 0 (0%) -
Age, years 52 ± 21.06 57.2 ± 12.97 0,323
Arterial systolic pressure, mmHg 109.87 (102.5-149.3) 129.59 (108.33-157) 0.170
Arterial diastolic pressure, mmHg 65.6 (62.37-69.6) 74.46 (60-84.8) 0,061
Hospitalization duration 6 (5-10) 5 (3-8) 0,107
Duration of treatment to bleed stopped 2 (1-3) 1 (1-3) 0,103
Duration of treatment 6 (5-9) 2.5 (2-6) 0,007
Cost 11,100 (3,924) 53,970 (26,954) 0,001
Vitamin K (n=6) Vitamin K-Transamin (n=8) p value
Gender, male 3 (50%) 5 (62.5%) 0.480
Gender, female 3 (50%) 3 (37.5%) 1.000
Age, years 62.67 ± 19.45 64.62 ± 8.23 0,801
Arterial systolic pressure, mmHg 109.88 (102.56-132.5) 129.31 (110.14-139.71) 0,022
Arterial diastolic pressure, mmHg 61.47 (54.93-78.36) 72.1 (60.17-80.43) 0,117
Hospitalized duration 11 (8-14) 8.5 (4-13) 0,134
Duration of treatment to bleed stopped 4.5 (2-5) 2.5 (1-3) 0.010
Duration of treatment 10 (7-14) 5.5 (2-9) 0,007
Cost 22,200 (7,020) 86,737 (34,170) 0,002
Patient Characteristics in CTP Score A
Patient Characteristics in CTP Score B
Patient Characteristics in CTP Score C
Table 4. Patients Cahracteristics in CTP Score A, B and C
of analysis showed a significant difference (α=0.05) in 
comparison to the longer treatment improved in patients 
with CTP Score A, B and C (Table 4). Comparison of the 
lengths of time of treatment to improve in patients with 
vitamin K therapy in patients with CTP Score A and B were 
not significant, while comparison of the CTP Score A and C 
with B and C showed significant differences. The duration 
lengths of treatment to improve therapy in patients with 
vitamin K-transamin in patients with CTP Score A and B 
were not significant, while in comparison the CTP Score 
A and C with B and C it showed significant differences 
(α=0.05). The result of the CTP Score, duration of treatment 
to improve the comparison between patients using vitamin 
K and vitamin K-transamin was not significant at the 
CTP Score A and B, while the CTP Score C results were 
significant (α=0.05). Based on the cost of the use of vitamin 
K only and vitamin K-transamin in the study samples, the 
result was a significant difference in comparison with the 
cost of treatment using vitamin K and vitamin K-transamin 
liver cirrhosis in patients with CTP Score A, B, and C (Table 
6).
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Total Cost to treat all patients
Effectiveness
IDR 12,641 IDR 62,643
              0.44               0.58
Vitamin K Vitamin K-transamin
= IDR 28,731
IDR 12,641
44.44% cure rate
= IDR 108,006ACER
IDR 62,643
58.33% cure rate
Table 5. ACER in all patients.
CTP Score
Total Cost to treat all patients
Effectiveness
ACER IDR 5,550 IDR 44,975 
Total Cost to treat all patients
Effectiveness
ACER IDR 11,100 IDR 53,970
                0.20                   0.70
Total Cost to treat all patients
Effectiveness
IDR 22,200 IDR 86,737
                0.33
C
B
A
IDR 86,737
100% cure rate
IDR 5,550
100% cure rate
IDR 11,100
20% cure rate
IDR 22,200
33.33% cure rate
Vitamin K-transaminVitamin K
83.33% cure rate
IDR 44,975
IDR 53,970
70% cure rate
= IDR 5,550 = IDR 54,186
 = IDR 55,500  = IDR 77,100
ACER = IDR 67,272  = IDR 86,737
1
1
0.83
Table 6. ACER in patients with CTP Score A, B and C.
in deterioration in the portal venous outflow, vascular 
micro thrombosis secondary to vascular ischemia and 
infarction may lead to the heart, with the loss of liver tissue 
(parenchymal extinction) being replaced by fibrotic tissue.
(20) The incident is most commonly caused by portal PVT 
that can contribute to significant morbidity and mortality. 
Cirrhotic patients with PVT should be screened for varices 
and then anti coagulated with low-molecular-weight heparin 
for at least a 6-month period. Newer evidence suggests that 
prophylactic anticoagulation in patients with cirrhosis may 
have a role in clinical management with decreased incidence 
of PVT and improved survival.(21)
 The patients characteristics can be seen in Table 3, 
while patients characteristics based on CTP classification can 
be seen in Table 4. p value indicates significant difference if 
p ≤ 0.05. In this study, there was one group with a number 
of samples less than 6, and it was CTP score B group using 
vitamin K with just 5 subjects. This was due to the limitation 
of hepatic cirrhosis patients with hematemesis-melena.
Discussion
One of the important pharmacist’s responsibilities in 
clinical pharmacy is to ensure good therapeutic outcome 
and pharmaceutical care which must not only be safe and 
effective, but also have a high value from economic and 
humanistic aspects. In fact, pharmacy profession would not 
succeed in their role to provide pharmaceutical care without 
pharmaco-economic knowledge.(17) Therefore, pharmaco-
economic evaluation like CEA which compares cost and 
effectiveness of therapy is needed.(18,19) The cost of 
transamin is higher than the cost of vitamin K, and to know 
whether addition of transamin in vitamin K monotherapy is 
needed in clinical practice, cost-effectiveness evaluation is 
required.
 In this research, the cause of the incident of 
hematemesis-melena was not confirmed. PVT is caused 
by increased hepatic resistance in cirrhosis, resulting 
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 The difference of liver severity will take effect on 
therapeutic effectiveness. The higher the liver damage, the 
lower the therapeutic effectiveness, due to decrease of liver 
function for coagulation factor synthesis (1,22), and if there 
is any hepatocellular disease or if the liver cell couldn’t 
synthesize blood coagulation factor, vitamin K given to 
patients wouldn’t be effective(23).
 Beside CTP Score, there is another instrument used to 
classify the severity of the liver damage, which is a newer 
method called model of end stage liver disease (MELD). 
There are some benefits of MELD, like no subjective 
assessment like CTP score (ascites, hepatic encephalopathy), 
but hepatologists generally do not use MELD because not 
all laboratories use internationalized ratio (INR) which is 
one of MELD components as coagulation marker in hepatic 
cirrhosis patient, and there is no clear value limitation on 
MELD. Besides that, MELD scoring needs calculation, 
therefore quick and simple measurement couldn’t be 
applied.(24)
 In Indonesia, the biggest risk factor as the cause of 
hepatic cirrhosis progression of hepatitis C and B infections 
followed by hemochromatosis(25) rather than alcohol, 
because of the difference between the amount of alcohol 
consumed by people in western countries than people 
in Indonesia. The development of hepatitis C to hepatic 
cirrhosis usually take years or decades, with average of 
20 years.(26) Most of hepatic cirrhosis patients are elderly 
people, usually in the range of 52-69 years old due to 
hepatic cirrhosis development which takes years or decades. 
From this study it is known that hepatic cirrhosis symptoms 
appears averagely at the age of 51 years and culminates at 
the range of 52-69 years.
 In this study bleeding mostly stopped at the first day 
after medication, although the patient had bled for days 
before hospitalized. This is in accordance with literature that 
claims when vitamin K is given parenterally, prothrombin 
time (PT) may need 12 to 24 hours to normal, although 
improvement may happen in 1 to 2 hours(27), whereas 
transamin has t1/2 = 2 hours(28). Therefore, it is most likely 
that patient’s bleeding could be stopped at the first day of 
treatment.
 Anti-fibrinolytic therapy has been shown to be useful 
in controlling bleeding in some conditions, especially in 
patients with gastric erosion and also in esophageal varices. 
Anti-fibrinolytic effect is not associated with improved 
systemic fibrinolysis, but more due to the inhibition of local 
fibrinolysis in gastroduodenal mucosa.(10) Therefore, the 
use of transamin in addition to the use of vitamin K can be 
an option, but there is no sufficient evidence supporting a 
recommendation on the use of transamin in the treatment 
Conclusion
The use of vitamin K therapy is more cost-effective than 
combination therapy of vitamin K-transamin in all patients 
with liver cirrhosis and hematemesis-melena, and in 
of gastrointestinal bleeding and bleeding from varices.(7) 
Regardless of the fact there is an evidence that transamin 
is a useful treatment for refractory bleeding due to gastric 
antral vascular ectasia in patients with cirrhosis.(29)
 Comparative effectiveness based on 
pharmacoeconomics reviews, performed by calculating 
the percentage of patients with cirrhosis of the liver with 
hematemesis melena ≤ 1 day in all patients and in patients 
with CTP Score A and B, as well as old treatment until the 
bleeding that stopped ≤ 3 days in patients with CTP Score C.
 Data were analyzed using cost-effectiveness grid and 
ACER. From the cost-effectiveness in the table grid (Table 
2) it can be seen that vitamin K has a dominant outcome 
in patients with CTP Score A and trade off on all patients 
as well as patients with CTP Score B and C. Consider 
further follow up on the results of the trade off is using 
ACER. From the dominant finding in the results, it can be 
seen that treatment with vitamin K have a lower cost with 
higher effectiveness than vitamin K-transamin, so it can 
be concluded that vitamin K is more cost-effective than 
vitamin K-transamin.
 Based on the calculation of ACER (Table 5 and 6), it 
showed the value of vitamin K was smaller than the vitamin 
K-transamin, so it can be concluded that vitamin K is more 
cost-effective than vitamin K-transamin in all patients as 
well as in patients with CTP Score A, B, and C.
 There are some limitations of this study including that 
of the number of samples which was too small, because it was 
taken from 1 hospital even in 2 years, and that’s why the data 
were not homogenous and the distribution was not normal 
either. We recommend that in the future studies using more 
samples with a longer time span should be carried out so the 
samples can be homogeneous and have normal distribution. 
The next limitation was the observed cost, in which this 
study only examined the cost of drugs, while other costs 
such as hospital and physician costs, laboratory costs, etc., 
were not observed. Another limitation was that the outcome 
of treatment was observed only until the bleeding stopped 
(the duration), other outcomes associated with bleeding 
such as PT was not observed. PT is a laboratory test needed 
to evaluate blood coagulation rate. Decrease of PT is an 
expected result from bleeding medication.
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patients with CTP score A, B, and C. This conclusion should 
be regarded with caution due to its limitation and further 
research is needed.
 Suggestion is given for further research using a 
prospective design so that the results obtained can be 
representative of the actual condition of the patient and 
confounding variables can be better controlled so as to 
obtain a good study of the relationship between risk factors 
and effects. In addition, the number of samples should be 
enlarged in order to get more homogeneous data and normal 
distribution, other components of cost such as cost of 
hospital, doctor, etc. could be calculated, not only the cost of 
therapy vitamin K or vitamin K-transamin, and the outcome 
observed is not only of the duration of bleeding, but also 
Prothrombin Time, side effects, and other factors that affect 
bleeding in patients.
